EBS FY 2013 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$430M

FY 2013 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$313M+10.9% YoY

Gross Profit

$131M41.8% margin

Operating Income

$43M13.7% margin

Net Income

$31M10.0% margin

EPS (Diluted)

$0.85

Cash Flow

Operating Cash Flow

$97M

Free Cash Flow

$55M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$627M

Total Liabilities

$137M

Stockholders' Equity

$490M

Cash & Equivalents

$179M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$313M	$282M	+10.9%
Gross Profit	$131M	$113M	+16.1%
Operating Income	$43M	$37M	+17.1%
Net Income	$31M	$24M	+32.4%